Filing Details

Accession Number:
0001104659-20-137408
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-12-18 16:04:16
Reporting Period:
2020-12-16
Accepted Time:
2020-12-18 16:04:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1760542 Hookipa Pharma Inc. HOOK Pharmaceutical Preparations (2834) 815395687
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1768208 Igor Matushansky C/O Hookipa Pharma Inc.
350 Fifth Avenue, 72Nd Floor, Suite 7240
New York NY 10118
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-12-16 640 $0.10 56,774 No 4 M Direct
Common Stock Disposition 2020-12-16 380 $11.70 56,394 No 4 S Direct
Common Stock Acquisiton 2020-12-17 19,360 $0.10 75,754 No 4 M Direct
Common Stock Disposition 2020-12-17 11,501 $11.70 64,253 No 4 S Direct
Common Stock Acquisiton 2020-12-17 29,628 $0.10 93,881 No 4 M Direct
Common Stock Disposition 2020-12-17 16,478 $11.76 77,403 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-12-16 640 $0.00 640 $0.10
Common Stock Stock Option (Right to Buy) Disposition 2020-12-17 31,656 $0.00 31,656 $0.10
Common Stock Stock Option (Right to Buy) Disposition 2020-12-17 11,367 $0.00 11,367 $0.10
Common Stock Stock Option (Right to Buy) Disposition 2020-12-17 5,965 $0.00 5,965 $0.10
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
39,735 2026-12-31 No 4 M Direct
8,079 2026-12-31 No 4 M Direct
14,208 2026-12-31 No 4 M Direct
7,669 2026-12-31 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were in connection with the satisfaction of tax obligations and the shares retained upon exercise remain subject to a lockup agreement which expires on March 8, 2021.
  2. 25% of this option vested and became exercisable on March 1, 2018, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 129,212 shares and the Reporting Person has exercised his option to purchase 121,133 shares.
  3. 25% of this option vested and became exercisable on January 1, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 45,466 shares and the Reporting Person has exercised his option to purchase 31,258 shares.
  4. 25% of this option vested and became exercisable on January 1, 2020, with the remainder vesting in 12 equal quarterly installments thereafter. This option was initially for 13,634 shares and the Reporting Person has exercised his option to purchase 5,965 shares.